Case-Control Studies *Drinking Water Humans Nitrates/adverse effects/analysis Odds Ratio Risk Factors *Urinary Bladder Neoplasms/chemically induced/epidemiology Bladder cancer Drinking water Meta-analysis Nitrate

非肌层浸润性膀胱癌 经尿道激光 传统电切手术 Meta分析

bladder cancer incidence meta-analyses metformin treatment outcome commercial or financial relationships that could be construed as a potential conflict of interest.

Chemotherapy Adjuvant Cisplatin/therapeutic use Female Humans Male Muscles Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/drug therapy *Bladder cancer *Chemotherapy *Individual participant data *Meta-analysis *Systematic review

Cystectomy/*methods Electrosurgery/*methods Humans Neoplasm Invasiveness Treatment Outcome Urethra Urinary Bladder Neoplasms/pathology/*surgery Bipolar Meta-analysis Monopolar Transurethral bladder tumor resection

膀胱肿瘤 根治性膀胱切除术 机器人 剖腹术 Meta分析

Case-Control Studies Diet/adverse effects *Diet Mediterranean Humans Incidence Rare Diseases Risk Factors *Urinary Bladder Neoplasms/epidemiology/etiology Bladder Cancer Dietary Inflammatory Index Mediterranean Diet Meta-analysis Western Diet

Cystectomy/methods *Enhanced Recovery After Surgery Humans Length of Stay Meta-Analysis as Topic Postoperative Complications/surgery *Urinary Bladder Neoplasms/surgery

en bloc resection high-risk nonmuscle-invasive bladder cancer reresection systematic review and meta-analysis commercial or financial relationships that could be construed as a potential conflict of interest.

Administration Intravesical BCG Vaccine/therapeutic use Humans Neoplasm Recurrence Local/prevention & control Network Meta-Analysis *Urinary Bladder Neoplasms/drug therapy/pathology Bladder cancer Intermediate risk Intravesical therapy Non–muscle-invasive bladder cancer

Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use B7-H1 Antigen/antagonists & inhibitors Carcinoma/*drug therapy/immunology/mortality/pathology Clinical Decision-Making Female Humans Immune Checkpoint Inhibitors/adverse effects/*therapeutic use Male Middle Aged Patient Selection Progression-Free Survival Time Factors Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology Urothelium/*drug effects/immunology/pathology Immune-checkpoint inhibitor Meta-analysis Programmed death-ligand 1 Urothelial carcinoma interests/personal relationships which may be considered as potential competing interests: The authors certify that all conflicts of interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the article are listed as follows: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Jansen Lilly MSD Olympus Pfizer Pierre Fabre Roche Sanochemia Sanofi Takeda Urogen and Wolff. All remaining authors have declared no conflicts of interest.

非肌层浸润性膀胱癌 整块切除 经尿道膀胱肿瘤切除术 Meta分析

Carcinoma Transitional Cell/pathology Disease-Free Survival Humans *Neoplasm Staging Prognosis Urinary Bladder/*pathology Urinary Bladder Neoplasms/*pathology Bladder urothelial carcinoma Meta-analysis Squamous differentiation

Her2 bladder cancer clinical significance meta-analysis prognostic value commercial or financial relationships that could be construed as a potential conflict of interest.

Case-Control Studies Humans Male NAD(P)H Dehydrogenase (Quinone)/*genetics Polymorphism Single Nucleotide Prostatic Neoplasms/*genetics Urinary Bladder Neoplasms/*genetics NQO1 gene meta-analysis polymorphism prostatic neoplasms urinary bladder neoplasms

alcohol bladder cancer dose-response meta-analysis systematic review commercial or financial relationships that could be construed as a potential conflict of interest.

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.

Crohn's disease bladder cancer inflammatory bowel diseases meta-analysis ulcerative colitis commercial or financial relationships that could be construed as a potential conflict of interest.

Biomarkers Tumor/*metabolism Estrogen Receptor alpha/*metabolism Estrogen Receptor beta/*metabolism GATA3 Transcription Factor/*metabolism Humans Prognosis Urinary Bladder Neoplasms/diagnosis/*metabolism Gata3 bladder cancer estrogen receptors immunohistochemistry tumour markers commercial or financial relationships that could be construed as a potential conflict of interest.

Administration Intravesical BCG Vaccine/*adverse effects/*therapeutic use Humans Meta-Analysis as Topic Randomized Controlled Trials as Topic *Systematic Reviews as Topic Urinary Bladder Neoplasms/*drug therapy